Search Results

You are looking at 1 - 10 of 443 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of

Full access

Tanya E. Keenan and Sara M. Tolaney

predominant systemic therapy for most metastatic TNBC (mTNBC) is chemotherapy, but responses are often short-lived, and patients have a median overall survival (OS) of 12 to 18 months. 1 Therefore, improved therapies are urgently needed. Immunotherapy has

Full access

Saber Amin, Michael Baine, Jane Meza, and Chi Lin

median survival in patients with BMs from renal cell carcinoma by more than 9 months (16.6 vs 7.2 months). 21 The development of immunotherapeutics offers an exciting opportunity for the treatment of BMs. 12 Immunotherapy has shown great success in the

Full access

Pooja Ghatalia and Elizabeth R. Plimack

metastatic UC. Additionally, early data from clinical trials combining chemotherapy with immunotherapy in the frontline setting are also now available. This article reviews the data that led to FDA approval of these agents for mUC in patients who are

Full access

David D. Chism

OS of 6 to 9 months. 12 – 14 Both the unmet need for second-line therapies for bladder cancer and a resurgence of immunotherapy in other solid tumors coincided to provide the backdrop for the immunotherapy launch into bladder cancer. Ipilimumab, a

Full access

Jarushka Naidoo

Kimmel Comprehensive Cancer Center at Johns Hopkins, discussed the busy and growing area of biomarker testing for immunotherapy. Biomarkers are defined as “cellular, biochemical or molecular alterations that are measurable in biological media, such as

Full access

Anthony J. Olszanski

Immunotherapy has grabbed our attention [in oncology], and it is not the end of the story,” declared Anthony J. Olszanski, RPh, MD, Associate Professor, Director of the Phase I Developmental Therapeutics Program, and Director of the Medical

Full access

Matthew A. Gubens

Matthew A. Gubens, MD, MS, Assistant Clinical Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discussed the past, present, and future of immunotherapies for non–small cell lung cancer (NSCLC) at the NCCN 22nd Annual

Full access

Brandon A. Dyer, Dmitriy Zamarin, Ramez N. Eskandar, and Jyoti M. Mayadev

Clinical Rationale to Explore Immunotherapy in Cervical Cancer Cervical cancer (CC) affects an estimated 12,900 women and accounts for 4,100 deaths annually in the United States, and is the most common gynecologic cancer worldwide. 1 The

Full access

Mary F. Mulcahy and Al B. Benson III

: 30 – 36 . 34 Harris JE Ryan L Hoover HC Jr . Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283 . J Clin Oncol 2000 ; 18 : 148